---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060202"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T14:55:03.769157+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Personalis Q3 revenue up 23% to $18.2M; raises FY2023 guidance

## Summary
- Revenue $18.2M (+23% YoY); net loss $29.1M, EPS -$0.60 including $5.6M impairment.
- Full-year 2023 revenue guidance raised to $73-74M (prior $70-72M); Q4 guided $19-20M.
- Pharma/enterprise revenue $15.8M (+7% YoY); Natera contributed $7.9M.
- TRACERx data: NeXT Personal up to 4x sensitivity vs other liquid biopsies; detects lung cancer 6-11 months before imaging.
- Cash $120.7M; FY2023 cash usage <$70M vs $119M in 2022.

## SEC filing metadata
- accession: 0000950170-23-060202
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000095017023060202/0000950170-23-060202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000095017023060202/psnl-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060202
- JSON: https://secwatch.observer/filing/0000950170-23-060202.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060202.txt

## Key facts
- Earnings Releases
  Personalis, Inc. reported the third quarter ended September 30, 2023 results: revenue $18.2 million, net income $29.1 million, EPS $0.60. Guidance raised.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $18.2 million
  - Net income: $29.1 million
  - EPS: $0.60
  - Guidance: raised
  - Result: reported results
  source text: reference in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Personalis Reports Third Quarter 2023 Financial Results Increased third quarter revenue 23% to $18.2 million and increased full year guidance Presented data supporting Next Personal’s market leading sensitivity for cancer recurrence detection FREMONT, Calif. – November 7, 2023 –
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527753/000095017023060202/0000950170-23-060202-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.